格列喹酮对糖尿病肾脏疾病改善作用的效果观察

发布时间：2018-05-10 14:04

本文选题：糖尿病肾脏疾病 + 格列喹酮　；参考：《中国糖尿病杂志》2017年10期

【摘要】：目的评价格列喹酮用于糖尿病肾脏疾病(DKD)治疗的临床疗效及安全性。方法将60例DKD患者随机分为格列喹酮组和胰岛素组,比较两组治疗前后尿白蛋白/肌酐比值(ACR)、尿β2微球蛋白(β2-MG)、血糖控制及胰岛功能指标的变化和差异。结果治疗24周后,两组ACR均较治疗前降低(P0.05)。24周时,格列喹酮组ACR低于胰岛素组[5.28(2.74,8.85)vs 11.87(7.18,19.35)mg/mmol,P=0.001]。格列喹酮组尿β2微球蛋白较治疗前下降,且低于胰岛素组[(0.64±0.40)vs(1.24±0.90)mg/L(P0.01)]。两组血糖控制程度相当,但格列喹酮组低血糖事件少于胰岛素组。治疗后格列喹酮组IR改善优于胰岛素组。结论格列喹酮改善DKD的疗效可能与其治疗后肾小球滤过、肾小管重吸收功能的改善、更少低血糖风险及IR的改善等作用相关。
[Abstract]:Objective to evaluate the clinical efficacy and safety of gliaqualone in the treatment of diabetic kidney disease (DKD). Methods 60 patients with DKD were randomly divided into gliaqualone group and insulin group. The changes and differences of urinary albumin / creatinine ratio (ACR), urinary 尾 2-microglobulin (尾 2-MGG), blood glucose control and islet function were compared before and after treatment. Results after 24 weeks of treatment, ACR in both groups was significantly lower than that before treatment (P0.05n.24), and the ACR in gliqualone group was lower than that in insulin group (5.280.74 卤8.85 vs 11.877.187.1819.35mg-1 路mol / P0. 001). Urinary 尾 2 microglobulin in gliqualone group was lower than that in insulin group (0.64 卤0.40)vs(1.24 卤0.90 mg / L P 0.01). The control degree of blood glucose in the two groups was similar, but the hypoglycemic events in gliaquinone group were lower than those in insulin group. After treatment, the improvement of IR in gliaqualone group was better than that in insulin group. Conclusion the efficacy of gliaqualone in improving DKD may be related to the improvement of glomerular filtration, renal tubular reabsorption, less hypoglycemia risk and IR after treatment.
【作者单位】：山东大学齐鲁医院内分泌科;清华长庚医院血液科;
【基金】：国家自然科学基金(81370943、81500631) 山东省自然科学基金(BS2015YY011)
【分类号】：R587.2;R692.9

【相似文献】